← All trials
NCT06466785
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Sep 30, 2027
- First posted
- Jun 20, 2024
- Last posted
- Jun 24, 2024
- Enrollment
- 429
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Genexine, Inc.Lead sponsor
- Genexine, Inc.Collaborator
- Genexine, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.